Evidence map›Paper›PMID 36520530›Full record

ArticleJMIR research protocols2022

Case-Finding Strategies for Drug-Resistant Tuberculosis: Protocol for a Scoping Review.

Susanna S Van Wyk, Marriott Nliwasa, James A Seddon, Graeme Hoddinott, Lario Viljoen, Emmanuel Nepolo, Gunar Günther, Nunurai Ruswa, Hsien-Ho Lin, Stefan Niemann and 3 more

Abstract read
In one paragraph

Article in JMIR research protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Susanna S Van WykCentre for Evidence Based Health Care, Division of Epidemiology and Biostatistics, Department of Global Health, Stellenbosch University, Cape Town, South Africa.ORCID https://orcid.org/0000-0001-7367-6691
Marriott NliwasaHelse Nord Tuberculosis Initiative, Kamuzu University of Health Sciences, Blantyre, Malawi.ORCID https://orcid.org/0000-0002-3100-5512
James A SeddonDesmond Tutu Tuberculosis Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-2296-2302
Graeme HoddinottDesmond Tutu Tuberculosis Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID https://orcid.org/0000-0001-5915-8126
Lario ViljoenDesmond Tutu Tuberculosis Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID https://orcid.org/0000-0003-4039-6639
Emmanuel NepoloDepartment of Human, Biological and Translational Medical Science, School of Medicine, University of Namibia, Windhoek, Namibia.ORCID https://orcid.org/0000-0003-4302-5606
Gunar GüntherDepartment of Human, Biological and Translational Medical Science, School of Medicine, University of Namibia, Windhoek, Namibia.ORCID https://orcid.org/0000-0002-2217-4322
Nunurai RuswaMinistry of Health and Social Services, Windhoek, Namibia.ORCID https://orcid.org/0000-0003-1764-3574
Hsien-Ho LinInstitute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan.ORCID https://orcid.org/0000-0002-7481-6016
Stefan NiemannMolecular and Experimental Mycobacteriology Group, Forschungszentrum Borstel, Borstel, Germany.ORCID https://orcid.org/0000-0002-6604-0684
Neel R GandhiDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.ORCID https://orcid.org/0000-0002-1665-299X
N Sarita ShahDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.ORCID https://orcid.org/0000-0001-6069-0857
Mareli ClaassensDepartment of Human, Biological and Translational Medical Science, School of Medicine, University of Namibia, Windhoek, Namibia.ORCID https://orcid.org/0000-0002-5927-284X

Funding

Emory/Georgia TB Research Advancement Center (TRAC)P30AI168386 · NIAID · EMORY UNIVERSITY · PI Neel Rajnikant Gandhi · 2022 to 2026
$5.8M
Mentorship in Patient-Oriented Research in Tuberculosis, HIV and Global HealthK24AI114444 · NIAID · EMORY UNIVERSITY · PI GANDHI, NEEL RAJNIKANT · 2014 to 2023
$1.8M
Medical Research Council MR/R007942/1Medical Research Council MR/T008814/1NIAID NIH HHS K24 AI114444NIAID NIH HHS P30 AI168386
6 · The paper itself

Abstract

backgroundTransmission of drug-resistant tuberculosis (DR-TB) is ongoing. Finding individuals with DR-TB and initiating treatment as early as possible is important to improve patient clinical outcomes and to break the chain of transmission to control the pandemic. To our knowledge systematic reviews assessing effectiveness, cost-effectiveness, acceptability, and feasibility of different case-finding strategies for DR-TB to inform research, policy, and practice have not been conducted, and it is unknown whether enough research exists to conduct such reviews. It is unknown whether case-finding strategies are similar for DR-TB and drug-susceptible TB and whether we can draw on findings from drug-susceptible reviews to inform decisions on case-finding strategies for DR-TB.

objectiveThis protocol aims to describe the available literature on case-finding for DR-TB and to describe case-finding strategies.

methodsWe will screen systematic reviews, trials, qualitative studies, diagnostic test accuracy studies, and other primary research that specifically sought to improve DR-TB case detection. We will exclude studies that invited individuals seeking care for TB symptoms, those including individuals already diagnosed with TB, or laboratory-based studies. We will search the academic databases including MEDLINE, Embase, The Cochrane Library, Africa-Wide Information, CINAHL, Epistemonikos, and PROSPERO with no language or date restrictions. We will screen titles, abstracts, and full-text articles in duplicate. Data extraction and analyses will be performed using Excel (Microsoft Corp).

resultsWe will provide a narrative report with supporting figures or tables to summarize the data. A systems-based logic model, developed from a synthesis of case-finding strategies for drug-susceptible TB, will be used as a framework to describe different strategies, resulting pathways, and enhancements of pathways. The search will be conducted at the end of 2021. Title and abstract screening, full text screening, and data extraction will be undertaken from January to June 2022. Thereafter, analysis will be conducted, and results compiled.

conclusionsThis scoping review will chart existing literature on case-finding for DR-TB-this will help determine whether primary studies on effectiveness, cost-effectiveness, acceptability, and feasibility of different case-finding strategies for DR-TB exist and will help formulate potential questions for a systematic review. We will also describe case-finding strategies for DR-TB and how they fit into a model of case-finding pathways for drug-susceptible TB. This review has some limitations. One limitation is the diverse, inconsistent use of intervention terminology within the literature, which may result in missing relevant studies. Poor reporting of intervention strategies may also cause misunderstanding and misclassification of interventions. Lastly, case-finding strategies for DR-TB may not fit into a model developed from strategies for drug-susceptible TB. Nevertheless, such a situation will provide an opportunity to refine the model for future research. The review will guide further research to inform decisions on case-finding policies and practices for DR-TB. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/40009.

Indexed as

acceptabilitycase findingcase-finding strategiesclinicaldatadrugdrug-resistantdrug-resistant tuberculosisfeasibilityliteraturemodelpolicypublic healthresearchsystematic reviewtransmissiontreatmenttuberculosis

Identifiers

PMID36520530
PMCPMC9801265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.